The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...
Sanofi has licensed an oral IL-17A inhibitor from C4X Discovery. The deal positions Sanofi to deliver an oral alternative to injectable anti-IL-17 antibodies such as Novartis' Cosentyx and Eli Lilly’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results